TNFRSF9 and neoplasm: Regarding MM, anti-CD137 agonistic mAb treatment significantly reduced systemic tumor burden in a murine syngeneic disseminated myeloma model (5TGM1), which closely resembles human MM [57, 58], suggesting the potential utility of anti-CD137 agonistic mAbs.